{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kim GD"],"funding":["Korea Health Industry Development Institute","National Research Foundation of Korea"],"pagination":["e011636"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12097017"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(5)"],"pubmed_abstract":["Background
Immune checkpoint inhibitors (ICIs) have transformed treatment and have provided significant clinical benefits and durable responses for patients with advanced non-small cell lung cancer (NSCLC). However, only a small percentage of patients respond to ICI treatment, and immune-related adverse events (irAEs) leading to treatment discontinuation remain challenging. Despite the recognized need for biomarkers to predict both the efficacy of ICIs and the risk of irAEs, such biomarkers are yet to be clearly identified.Methods
In this study, we performed single-cell RNA sequencing (scRNA-seq) of peripheral blood mononuclear cells (PBMCs) from 33 patients with NSCLC before ICIs treatment. To validate our findings, we reanalyzed public scRNA-seq data, conducted a cytometr"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Single-cell RNA sequencing of baseline PBMCs predicts ICI efficacy and irAE severity in patients with NSCLC."],"pmcid":["PMC12097017"],"funding_grant_id":["RS-2019-NR040068","RS-2024-00403622","RS-2022-KH130308","RS-2022-NR071878","RS-2024-00335026"],"pubmed_authors":["Chung C","Lee JE","Kang DH","Sun P","Park J","Kim GD","Shin SI","Kang YE"],"additional_accession":[]},"is_claimable":false,"name":"Single-cell RNA sequencing of baseline PBMCs predicts ICI efficacy and irAE severity in patients with NSCLC.","description":"Background
Immune checkpoint inhibitors (ICIs) have transformed treatment and have provided significant clinical benefits and durable responses for patients with advanced non-small cell lung cancer (NSCLC). However, only a small percentage of patients respond to ICI treatment, and immune-related adverse events (irAEs) leading to treatment discontinuation remain challenging. Despite the recognized need for biomarkers to predict both the efficacy of ICIs and the risk of irAEs, such biomarkers are yet to be clearly identified.Methods
In this study, we performed single-cell RNA sequencing (scRNA-seq) of peripheral blood mononuclear cells (PBMCs) from 33 patients with NSCLC before ICIs treatment. To validate our findings, we reanalyzed public scRNA-seq data, conducted a cytometr","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-06-03T02:43:15.21Z","creation":"2026-04-23T03:10:34.369Z"},"accession":"S-EPMC12097017","cross_references":{"pubmed":["40404203"],"doi":["10.1136/jitc-2025-011636"]}}